FGFR2 and breast carcinoma: Though, none of them has reached the clinical phase as yet and there are many hurdles to be overcome, there is enough encouraging evidence suggesting that targeting FGFR2 along with other FGFRs in certain subtypes of breast cancer could be a valuable approach in the future [84]–[88].